NASDAQ: GENE - Genetic Technologies Limited

छह महीने के लिए लाभप्रदता: -1.92%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Genetic Technologies Limited


कंपनी के बारे में Genetic Technologies Limited

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

अधिक जानकारी
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

IPO date 2005-09-02
ISIN US37185R3075
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://genetype.com
Цена ао 0.765
प्रति दिन मूल्य परिवर्तन: 0% (0.765)
प्रति सप्ताह मूल्य परिवर्तन: 0% (0.765)
प्रति माह मूल्य परिवर्तन: 0% (0.765)
3 महीने में कीमत में बदलाव: 0% (0.765)
छह महीने में कीमत में बदलाव: -1.92% (0.78)
प्रति वर्ष मूल्य परिवर्तन: -73.06% (2.84)
3 वर्षों में मूल्य परिवर्तन: -62.81% (2.0569)
5 वर्षों में मूल्य परिवर्तन: -72.58% (2.79)
वर्ष की शुरुआत से मूल्य परिवर्तन: 0% (0.765)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 44.57 1
P/BV 186.62 1
P/E 0 0
EV/EBITDA -29.87 0
कुल: 1.75

क्षमता

नाम अर्थ श्रेणी
ROA, % -114.22 0
ROE, % -184.98 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.0766 10
कुल: 9.6

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 77604.62 10
लाभप्रदता Ebitda, % 87.88 9
लाभप्रदता EPS, % 8989 10
कुल: 9.2

संस्थानों आयतन शेयर करना, %
Morgan Stanley 17289 0.45
Rhumbline Advisers 3739 0.1
UBS Group AG 2994 0.08
Wells Fargo & Company 130 0
SIMPLEX TRADING, LLC 18 0



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Mr. Simon Morriss Chief Executive Officer 262.57k
Mr. Carl S. Stubbings BSc Chief Commercial Officer 173.93k
Mr. Kevin Camilleri Chief Executive Officer of EasyDNA 167.85k
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant 119.53k
Mr. Mark Ziirsen CFO & Company Secretary 1963 (62 वर्ष)
Dr. Erika Spaeth Ph.D. Director of Clinical & Scientific Affairs

पता: Australia, Fitzroy, 60-66 Hanover Street - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://genetype.com